StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

ERASBullishERAS-0015 Phase 1 update and Phase 3 plannews
Medium materiality6/10

Erasca falls 5% as early RAS cancer data leave key questions unanswered

Nov 20, 2026, 9:43 AM EST1 sourcesAI-analyzed
Why it may matterVerify against the original reporting

The Phase 1 response rates and the stated plan for a Phase 3 trial imply potential future commercial opportunity if durability and confirmatory outcomes hold; however, the absence of DOR/PFS/OS data leaves the revenue impact uncertain until registrational efficacy is demonstrated.

AI summary

What happened, with direct paths to the underlying reporting

Erasca reported updated Phase 1 ERAS-0015 data showing a 44% confirmed ORR (11/25) in 2L+ KRAS G12X pancreatic cancer and stronger responses (69%) in a G12D/V subgroup, and said it plans to begin a Phase 3 pancreatic trial in H1 2027.

  • At a once-daily dose of 32 milligrams, ERAS-0015 produced a 44% confirmed objective response rate in 25 patients with previously treated pancreatic ductal adenocarcinoma harboring KRAS G12X mutations.
  • The 44% ORR corresponds to 11 patients with confirmed tumor responses.
  • In a 13-patient subgroup with G12D or G12V mutations the confirmed response rate was 69% (63% in eight G12D patients and 80% in five G12V patients).
  • The company said it plans to begin a Phase 3 pancreatic cancer trial in the first half of 2027.
  • The announcement did not provide median duration of response, progression-free survival or overall survival.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.